ClinicalTrials.gg
CompletedNCT03769168Updated Oct 16, 2025Results posted

An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)

A Phase 3 interventional study of Secukinumab in Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 9 countries. Open to participants aged 2 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
2 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Arthritis, Juvenile by Novartis — 6 open to participants now, 6 under way, none of them phase 3. Arthritis, Juvenile · Novartis.

Enrollment
6th of 12
55 · median 43
Started
2019
the only one that year
Phase 3
9 of 18
none open now
Registered
10th of 18
by date

Among the 18 studies in Arthritis, Juvenile by Novartis, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 9 in phase 3, and was the 10th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

6 of the 18 studies in Arthritis, Juvenile by Novartis are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Arthritis, Juvenile by Novartis, or all of them as a file.
02

Study summary

Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).

Read the detailed description

This study is an extension of a previous core study (NCT03031782 [CAIN457F2304]) aiming to assess the long-term efficacy, safety, and tolerability of secukinumab treatment in patients who completed the core study and chose to participate in the extension study. The primary objective was to gather comprehensive data on the efficacy and safety of secukinumab over an extended period.

At Week 104 of the core study, all eligible patients could opt to roll over to the extension study and continue receiving secukinumab at either 75 mg or 150 mg, as they were at the Week 100 visit of the core study. The treatment involved subcutaneous injections using pre-filled syringes (PFS). The duration of patient participation could range from a minimum of one year to a maximum of four years, or until one of the following conditions was met: the drug was locally approved, marketed, and reimbursed, secukinumab could be provided free of charge to patients in compliance with local guidelines, or a maximum of 4 years study duration.

During the extension study (starting from Week 108), to maintain a high proportion of clinically meaningful response during the entire duration of the extension study, the dosing options available, at the Investigator's discretion, were as follows:

  • The dose could be escalated from 75 mg to 150 mg for patients whose signs and symptoms were not fully controlled with the current dose of 75 mg and might improve with a higher dose as judged by the investigator
  • Further, the dose could be escalated to 300 mg for patients weighing 50 kg and over currently on the 150 mg dose whose signs and symptoms were not fully controlled and might improve further with an increase in dose as judged by the investigator
  • Dose escalation from secukinumab 75 mg to 300 mg had to be done in two steps (first 150 mg then 300 mg if the patient weighed 50 kg or over and based on the investigator's judgement), also considering the gap between the two escalations to review the response
03

Conditions studied

  • Juvenile Psoriatic Arthritis
  • Enthesitis Related Arthritis

Browse trials for

Keywords

  • JIA
  • JPsA
  • ERA
  • Secukinumab
  • ILAR
  • Juvenile Psoriatic Arthritis
  • Enthesitis Related Arthritis
04

Who can participate

Ages eligible
2 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients had to have participated in the core study CAIN457F2304 and completed the entire treatment period up to and including Week 104.
  • Patients had to be deemed by the investigator to benefit from continued secukinumab therapy.

Key Exclusion Criteria:

  • Patients with plans for administration of during the extension study period were excluded.
  • Patients taking any other concomitant biologic immunomodulating agent(s) except secukinumab were excluded.
  • Patients who were deemed not to be benefiting from the study treatment based on lack of improvement or worsening of their symptoms were excluded.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Group 1- Secukinumab 75 mg

    Participants initially received secukinumab 75mg subcutaneously once every four weeks in the extension study. If the signs and symptoms of the participants were not adequately controlled with the 75mg dose, as determined by the investigator, the dose could be escalated to 150mg subcutaneously. For patients weighing 50kg and over, the dose could further be escalated to 300mg subcutaneously every four weeks. The dose escalation from secukinumab 75mg subcutaneously to 300mg subcutaneously was to be implemented in two steps, with the first step being an increase to 150mg subcutaneously, followed by another escalation to 300mg subcutaneously, based on the judgement of the investigator.

    Drug: Secukinumab

  • Experimental
    Group 2 - Secukinumab 150 mg

    Participants initially received secukinumab 150mg subcutaneously once every four weeks in the extension study. If the signs and symptoms of the participants were not adequately controlled with the 150mg dose, as determined by the investigator, the dose could be escalated to 300mg subcutaneously.

    Drug: Secukinumab

Interventions

  • Secukinumab solution for subcutaneous injections was provided in PFS. Initially, participants continued to receive secukinumab at either 75 mg (in 0.5mL) or 150 mg (in 1mL) every 4 weeks, consistent with their dosage at the Week 100 visit of the core study. The dose could be escalated from 75 mg to 150 mg for patients whose signs and symptoms were not fully controlled, as judged by the investigator, with the current 75 mg dose. Furthermore, the dose could also be escalated to 300 mg every 4 weeks for patients weighing 50kg and over who were currently on the 150 mg dose and whose signs and symptoms were not well-controlled, as judged by the investigator. The dose escalation from secukinumab 75 mg to 300 mg was to be implemented in two steps (first 150 mg and then 300 mg based on the investigator's judgment). At each study treatment time point, one or two subcutaneous injections in the form of PFS were administered.

    Also known as: AIN457

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response

    The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ: Childhood Health Assessment Questionnaire): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain. It ranged from 0 (no disability) to 3 (very severe disability). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: C-reactive Protein (CRP) levels The JIA ACR 30 response was achieved if 3 of any 6 core set variables improved by at least 30% from baseline of the core study, and no more than 1 variable worsening more than 30%

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

Secondary outcomes

  1. Percentage of Participants With JIA ACR 50 Response

    The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 50 responses were achieved if 3 of any 6 core set variables improved by at least 50% from baseline of the core study, and no more than 1 variable worsening \> 30%

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  2. Percentage of Participants With JIA ACR 70 Response

    The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 70 responses were achieved if 3 of any 6 core set variables improved by at least 70%, from baseline of the core study, and no more than 1 variable worsening \> 30%

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  3. Percentage of Participants With JIA ACR 90 Response

    The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 90 responses were achieved if 3 of any 6 core set variables improved by at least 90% from baseline of the core study, and no more than 1 variable worsening \> 30%

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  4. Percentage of Participants With JIA ACR 100 Response

    The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 100 responses were achieved if 3 of any 6 core set variables improved with 100% from baseline of the core study, and no more than 1 variable worsening \> 30%

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  5. Number of Participants With Inactive Disease Status

    Inactive disease status was confirmed in a patient when all the following conditions were met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA lasting ≥15 minutes.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  6. Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Physician Global Assessment of Disease Activity

    The JIA ACR response criteria consisted of 6 core criteria, one of which was the physician global assessment of disease activity. this assessment was conducted using a 100 mm VAS score, where 0 represented the best disease activity and 100 the worst. The change from baseline of the core study of the physician global assessment of disease activity was measured, with a negative change indicating improvement.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  7. Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Parent's or Patients' Global Assessment of Overall Well-being

    The JIA ACR response criteria included six core components, one of which was the parent's or patients' global assessment of overall well-being. This assessment was conducted using a 100 mm VAS score, where 0 represented "very well" and 100 "very poor". The change from baseline of the core study in the parent's or patients' global assessment of overall well-being was measured, with a negative change indicating improvement

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  8. Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Functional Ability (CHAQ)

    The JIA ACR response criteria included six core components, one of which was the functional ability, measured by the CHAQ. The CHAQ questionnaire consisted of 30 questions across 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each domain was scored on a 4-point scale, and the total score was calculated as the average of the scores for each domain. The total score ranged from 0 (no disability) to 3 (very severe disability). The change from baseline of the core study in the CHAQ was measured, with a negative change indicating improvement.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  9. Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Active Arthritis

    The JIA ACR response criteria included six core components, one of which was the number of joints with active arthritis. This was determined using the ACR definition, which identifies active arthritis as any joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity. The active joint count ranged from 0 to 73. The change from baseline of the core study in the number of active joints was measured, with a negative change indicating improvement.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  10. Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Limited Range of Motion

    The JIA ACR response criteria included six core components, one of which was the number of joints with limited range of motion. A total of 69 joints were assessed for limitation of motion. The change from baseline of the core study in the number of joints with limited range of motion was measured, with a negative change indicating improvement.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  11. Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - CRP Levels

    The JIA ACR response criteria included six core components, one of which was CRP levels, an inflammation biomarker. Serum concentrations of CRP were determined, and the change from baseline of the core study was assessed, with negative changes indicating improvement.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  12. Change From Baseline of Core Study CAIN457F2304 of 27-joint Juvenile Arthritis Disease Activity Score (JADAS-27)

    The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 27; where 0= no disease activity and 27= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 57 where 0= no disease activity and 57= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  13. Change From Baseline of Core Study CAIN457F2304 of 71-joint Juvenile Arthritis Disease Activity Score (JADAS-71)

    The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 71; where 0= no disease activity and 71= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 101 where 0= no disease activity and 101= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  14. Change From Baseline of Core Study CAIN457F2304 in Total Enthesitis Count

    The following 16 entheseal sites were assessed for the presence or absence of tenderness (enthesitis) on each side of the body: * Anterior Entheses: Greater trochanter of the Femur; Medial condyle of the femur; Lateral condyle of the femur * Posterior Entheses: Greater tuberosity of humerus; medial epicondyle of humerus; lateral epicondyle of humerus, Achilles tendon; and calcaneal insertion of the plantar fascia. Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites, The total enthesitis count ranged from 0 to 16. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  15. Change From Baseline of Core Study CAIN457F2304 in Total Dactylitis Count

    The dactylitis count was the number of fingers and toes presenting with swelling and inflammation. Swelling and inflammation on examination was recorded as either present (1) or absent (0) for each of the 20 sites, The total dactylitis count ranged from 0 to 20. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement

    Time frame: Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  16. Serum Concentrations of Secukinumab Over Time

    Serum concentration of secukinumab over time. Blood samples for pharmacokinetics were taken pre-dose at the scheduled time points.

    Time frame: Pre-dose at Week 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.

  17. Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs) of Secukinumab

    Number of participants with treatment-emergent Anti-Drug Antibodies (ADAs) of secukinumab. Blood samples were collected for immunogenicity (anti-AIN457 antibodies) assessments.

    Time frame: From baseline of the core study up to Week 312. Study week is defined with respect to the core study.

07

Results

Posted May 23, 2025

Participant flow

Participants were recruited in 24 centers across 9 countries

Participant flow — Overall Study
MilestoneGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mg
Started1936
Secukinumab escalated to 150 mg60
Secukinumab escalated to 300 mg214
Treated1935
Completed1012
Not completed924
Withdrew: Adverse event01
Withdrew: Lack of efficacy24
Withdrew: Post study access to treatment311
Withdrew: Physician decision14
Withdrew: Subject decision24
Withdrew: Guardian decision10

Outcome measures

PrimaryPercentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response

The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ: Childhood Health Assessment Questionnaire): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain. It ranged from 0 (no disability) to 3 (very severe disability). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: C-reactive Protein (CRP) levels The JIA ACR 30 response was achieved if 3 of any 6 core set variables improved by at least 30% from baseline of the core study, and no more than 1 variable worsening more than 30%

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Number · Percentage of Participants
Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response
Percentage of ParticipantsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104100 (79.1 to 100)100 (87.7 to 100)100 (91.7 to 100)
Week 116100 (79.1 to 100)96.9 (82.0 to 99.8)98.9 (88.2 to 99.9)
Week 128100 (78.1 to 100)100 (86.3 to 100)100 (90.9 to 100)
Week 140100 (78.1 to 100)100 (87.0 to 100)100 (91.3 to 100)
Week 15694.7 (71.9 to 99.7)100 (87.0 to 100)98.1 (88.4 to 99.9)
Week 18094.7 (71.9 to 99.7)97.0 (82.5 to 99.8)96.2 (85.7 to 99.3)
Week 208100 (78.1 to 100)100 (86.3 to 100)100 (90.9 to 100)
Week 23294.1 (69.2 to 99.7)100 (84.5 to 100)97.7 (86.5 to 99.9)
Week 26092.9 (64.2 to 99.6)96.2 (78.4 to 99.8)95.0 (81.8 to 99.1)
Week 284100 (73.2 to 100)95.7 (76.0 to 99.8)97.3 (84.2 to 99.9)
Week 308100 (69.9 to 100)100 (77.1 to 100)100 (85.4 to 100)
Week 31290.0 (54.1 to 99.5)100 (69.9 to 100)95.5 (75.1 to 99.8)
SecondaryPercentage of Participants With JIA ACR 50 Response

The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 50 responses were achieved if 3 of any 6 core set variables improved by at least 50% from baseline of the core study, and no more than 1 variable worsening \> 30%

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Number · Percentage of participants
Percentage of Participants With JIA ACR 50 Response
Percentage of participantsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 10494.7 (71.9 to 99.7)94.3 (79.5 to 99.0)94.4 (83.7 to 98.6)
Week 116100 (79.1 to 100)93.8 (77.8 to 98.9)96.1 (85.4 to 99.3)
Week 12894.4 (74.2 to 98.7)93.5 (77.2 to 98.9)93.9 (82.1 to 98.4)
Week 140100 (78.1 to 100)90.9 (74.5 to 97.6)94.1 (82.8 to 98.5)
Week 15694.7 (71.9 to 99.7)87.9 (70.9 to 96.0)90.4 (78.2 to 96.4)
Week 18094.7 (71.9 to 99.7)93.9 (78.4 to 98.9)94.2 (83.1 to 98.5)
Week 208100 (78.1 to 100)90.3 (73.1 to 97.5)93.9 (82.1 to 98.4)
Week 23294.1 (69.2 to 99.7)96.3 (79.1 to 99.8)95.5 (83.3 to 99.2)
Week 26092.9 (64.2 to 99.6)96.2 (78.4 to 99.8)95.0 (81.8 to 99.1)
Week 284100 (73.2 to 100)95.7 (76.0 to 99.8)97.3 (84.2 to 99.9)
Week 308100 (69.9 to 100)100 (77.1 to 100)100 (85.4 to 100)
Week 31290.0 (54.1 to 99.5)100 (69.9 to 100)95.5 (75.1 to 99.8)
SecondaryPercentage of Participants With JIA ACR 70 Response

The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 70 responses were achieved if 3 of any 6 core set variables improved by at least 70%, from baseline of the core study, and no more than 1 variable worsening \> 30%

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Number · Percentage of participants
Percentage of Participants With JIA ACR 70 Response
Percentage of participantsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 10494.7 (71.9 to 99.7)82.9 (65.7 to 92.8)87.0 (74.5 to 94.2)
Week 11694.7 (71.9 to 99.7)90.6 (73.8 to 97.5)92.2 (80.3 to 97.5)
Week 12894.4 (70.6 to 99.7)90.3 (73.1 to 97.5)91.8 (79.5 to 97.4)
Week 14088.9 (63.9 to 98.1)84.8 (67.3 to 94.3)86.3 (73.1 to 93.8)
Week 15694.7 (71.9 to 99.7)84.8 (67.3 to 94.3)88.5 (75.9 to 95.2)
Week 18089.5 (65.5 to 98.2)81.8 (63.9 to 92.4)84.6 (71.4 to 92.7)
Week 20894.4 (70.6 to 99.7)90.3 (73.1 to 97.5)91.8 (79.5 to 97.4)
Week 23288.2 (62.3 to 97.9)85.2 (65.4 to 95.1)86.4 (72.0 to 94.3)
Week 26092.9 (64.2 to 99.6)96.2 (78.4 to 99.8)95.0 (81.8 to 99.1)
Week 284100 (73.2 to 100)95.7 (76.0 to 99.8)97.3 (84.2 to 99.9)
Week 308100 (69.9 to 100)100 (77.1 to 100)100 (85.4 to 100)
Week 31290.0 (54.1 to 99.5)83.3 (50.9 to 97.1)86.4 (64.0 to 96.4)
SecondaryPercentage of Participants With JIA ACR 90 Response

The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 90 responses were achieved if 3 of any 6 core set variables improved by at least 90% from baseline of the core study, and no more than 1 variable worsening \> 30%

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Number · Percentage of participants
Percentage of Participants With JIA ACR 90 Response
Percentage of participantsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 10484.2 (59.5 to 95.8)74.3 (56.4 to 86.9)77.8 (64.1 to 87.5)
Week 11673.7 (48.6 to 89.9)75.0 (56.2 to 87.9)74.5 (60.1 to 85.2)
Week 12883.3 (57.7 to 95.6)77.4 (58.5 to 89.7)79.6 (65.2 to 89.3)
Week 14083.3 (57.7 to 95.6)72.7 (54.2 to 86.1)76.5 (62.2 to 86.8)
Week 15673.7 (48.6 to 89.9)75.8 (57.4 to 88.3)75.0 (60.8 to 85.5)
Week 18084.2 (59.5 to 95.8)69.7 (51.1 to 83.8)75.0 (60.8 to 85.5)
Week 20877.8 (51.9 to 92.6)71.0 (51.8 to 85.1)73.5 (58.7 to 84.6)
Week 23276.5 (49.8 to 92.2)81.5 (61.3 to 93.0)79.5 (64.2 to 89.7)
Week 26071.4 (42.0 to 90.4)84.6 (64.3 to 95.0)80.0 (63.9 to 90.4)
Week 28485.7 (56.2 to 97.5)95.7 (76.0 to 99.8)91.9 (77.0 to 97.9)
Week 30891.7 (59.8 to 99.6)88.2 (62.3 to 97.9)89.7 (71.5 to 97.3)
Week 31280.0 (44.2 to 96.5)83.3 (50.9 to 97.1)81.8 (59.0 to 94.0)
SecondaryPercentage of Participants With JIA ACR 100 Response

The JIA ACR response criteria consisted of 6 core criteria: * Physician global assessment of disease activity on a 0-100 mm VAS (0=very good and 100=very poor). * Parent's or patients' global assessment of overall well-being on a 0-100 mm VAS (0=very well and 100=very poor). * Functional ability (CHAQ): 30 questions across 8 domains assessing the child's functional abilities. The total score was calculated as the average of the scores for each domain (0 \[no disability\] to 3 \[very severe disability\]). * Number of joints with active arthritis (as per ACR definition), ranging from 0 to 73. * Number of joints with limited range of motion, ranging from 0 to 69. * Index of inflammation: CRP levels The JIA ACR 100 responses were achieved if 3 of any 6 core set variables improved with 100% from baseline of the core study, and no more than 1 variable worsening \> 30%

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Number · Percentage of participants
Percentage of Participants With JIA ACR 100 Response
Percentage of participantsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 10463.2 (38.6 to 82.8)57.1 (39.5 to 73.2)59.3 (45.1 to 72.1)
Week 11663.2 (38.6 to 82.8)62.5 (43.7 to 78.3)62.7 (48.1 to 75.5)
Week 12866.7 (41.2 to 85.6)54.8 (36.3 to 72.2)59.2 (44.3 to 72.7)
Week 14066.7 (41.2 to 85.6)57.6 (39.4 to 74.0)60.8 (46.1 to 73.8)
Week 15663.2 (38.6 to 82.8)60.6 (42.2 to 76.6)61.5 (47.0 to 74.4)
Week 18057.9 (34.0 to 78.9)54.5 (36.6 to 71.5)55.8 (41.4 to 69.3)
Week 20872.2 (46.4 to 89.3)58.1 (39.3 to 74.9)63.3 (48.3 to 76.2)
Week 23258.8 (33.5 to 80.6)63.0 (42.5 to 79.9)61.4 (45.5 to 75.3)
Week 26071.4 (42.0 to 90.4)65.4 (44.4 to 82.1)67.5 (50.8 to 80.9)
Week 28478.6 (48.8 to 94.3)78.3 (55.8 to 91.7)78.4 (61.3 to 89.6)
Week 30891.7 (59.8 to 99.6)76.5 (49.8 to 92.2)82.8 (63.5 to 93.5)
Week 31280.0 (44.2 to 96.5)75.0 (42.8 to 93.3)77.3 (54.2 to 91.3)
SecondaryNumber of Participants With Inactive Disease Status

Inactive disease status was confirmed in a patient when all the following conditions were met: * No joints with active arthritis * No uveitis * CRP value within normal limits for the laboratory where tested or, if elevated, not attributable to JIA * Physician's global assessment of disease activity score ≤ 10mm * Duration of morning stiffness attributable to JIA lasting ≥15 minutes.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Number · Percentage of Participants
Number of Participants With Inactive Disease Status
Percentage of ParticipantsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 10463.2 (38.6 to 82.8)65.7 (47.7 to 80.3)64.8 (50.6 to 77.0)
Week 11668.4 (43.5 to 86.4)71.9 (53.0 to 85.6)70.6 (56.0 to 82.1)
Week 12866.7 (41.2 to 85.6)64.5 (45.4 to 80.2)65.3 (50.3 to 77.9)
Week 14072.2 (46.4 to 89.3)63.6 (45.1 to 79.0)66.7 (52.0 to 77.9)
Week 15668.4 (43.5 to 86.4)72.7 (54.2 to 86.1)71.2 (56.7 to 82.5)
Week 18068.4 (43.5 to 86.4)54.5 (36.6 to 71.5)59.6 (45.1 to 72.7)
Week 20861.1 (36.1 to 81.7)67.7 (48.5 to 82.7)65.3 (50.3 to 77.9)
Week 23270.6 (44.0 to 88.6)66.7 (46.0 to 82.8)68.2 (52.3 to 80.9)
Week 26071.4 (42.0 to 90.4)65.4 (44.4 to 82.1)67.5 (50.8 to 80.9)
Week 28478.6 (48.8 to 94.3)78.3 (55.8 to 91.7)78.4 (61.3 to 89.6)
Week 30883.3 (50.9 to 97.1)82.4 (55.8 to 95.3)82.8 (63.5 to 93.5)
Week 31270.0 (35.4 to 91.9)75.0 (42.8 to 93.3)72.7 (49.6 to 88.4)
SecondaryChange From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Physician Global Assessment of Disease Activity

The JIA ACR response criteria consisted of 6 core criteria, one of which was the physician global assessment of disease activity. this assessment was conducted using a 100 mm VAS score, where 0 represented the best disease activity and 100 the worst. The change from baseline of the core study of the physician global assessment of disease activity was measured, with a negative change indicating improvement.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Score on a Scale
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Physician Global Assessment of Disease Activity
Score on a ScaleGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-40.0 ± 18.39-42.2 ± 20.43-41.4 ± 19.59
Week 116-40.3 ± 18.42-41.1 ± 20.35-40.8 ± 19.46
Week 128-40.4 ± 18.55-41.9 ± 21.33-41.3 ± 20.17
Week 140-39.0 ± 16.75-42.4 ± 19.18-41.2 ± 18.26
Week 156-39.7 ± 17.09-40.8 ± 20.72-40.4 ± 19.50
Week 180-38.5 ± 18.20-38.9 ± 21.71-38.8 ± 20.31
Week 208-39.0 ± 17.06-41.8 ± 19.45-40.8 ± 18.48
Week 232-38.4 ± 18.20-42.9 ± 20.86-41.1 ± 19.78
Week 260-37.6 ± 28.75-45.4 ± 20.74-42.7 ± 23.78
Week 284-43.6 ± 18.96-42.8 ± 20.53-43.1 ± 19.68
Week 308-43.8 ± 18.76-40.3 ± 20.51-41.7 ± 19.53
Week 312-44.2 ± 26.58-47.4 ± 22.05-46.0 ± 23.67
SecondaryChange From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Parent's or Patients' Global Assessment of Overall Well-being

The JIA ACR response criteria included six core components, one of which was the parent's or patients' global assessment of overall well-being. This assessment was conducted using a 100 mm VAS score, where 0 represented "very well" and 100 "very poor". The change from baseline of the core study in the parent's or patients' global assessment of overall well-being was measured, with a negative change indicating improvement

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Score on a Scale
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Parent's or Patients' Global Assessment of Overall Well-being
Score on a ScaleGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-47.1 ± 25.90-38.6 ± 27.74-41.6 ± 27.17
Week 116-45.4 ± 25.70-37.7 ± 26.39-40.5 ± 26.15
Week 128-46.8 ± 25.02-39.1 ± 26.69-41.8 ± 26.11
Week 140-41.1 ± 27.57-38.7 ± 27.06-38.7 ± 27.06
Week 156-46.1 ± 25.41-39.2 ± 27.15-41.8 ± 26.49
Week 180-45.5 ± 27.24-39.8 ± 27.48-41.9 ± 27.27
Week 208-47.6 ± 25.70-40.3 ± 28.13-43.0 ± 27.23
Week 232-39.6 ± 27.23-43.4 ± 28.20-41.9 ± 27.57
Week 260-44.8 ± 34.52-42.8 ± 29.31-43.5 ± 30.80
Week 284-51.6 ± 24.97-43.2 ± 31.23-46.4 ± 28.96
Week 308-49.8 ± 24.23-48.5 ± 31.93-49.1 ± 28.53
Week 312-48.9 ± 28.45-53.5 ± 30.31-51.4 ± 28.87
SecondaryChange From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Functional Ability (CHAQ)

The JIA ACR response criteria included six core components, one of which was the functional ability, measured by the CHAQ. The CHAQ questionnaire consisted of 30 questions across 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each domain was scored on a 4-point scale, and the total score was calculated as the average of the scores for each domain. The total score ranged from 0 (no disability) to 3 (very severe disability). The change from baseline of the core study in the CHAQ was measured, with a negative change indicating improvement.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Score on a Scale
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Functional Ability (CHAQ)
Score on a ScaleGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-0.599 ± 0.5490-0.636 ± 0.5967-0.623 ± 0.5754
Week 116-0.605 ± 0.5469-0.617 ± 0.5811-0.613 ± 0.5631
Week 128-0.647 ± 0.5196-0.685 ± 0.5570-0.672 ± 0.5388
Week 140-0.590 ± 0.4809-0.648 ± 0.5638-0.627 ± 0.5318
Week 156-0.645 ± 0.5275-0.644 ± 0.5763-0.644 ± 0.5537
Week 180-0.658 ± 0.5541-0.625 ± 0.5779-0.637 ± 0.5641
Week 208-0.667 ± 0.4832-0.625 ± 0.5293-0.640 ± 0.5082
Week 232-0.610 ± 0.5411-0.681 ± 0.5825-0.653 ± 0.5615
Week 260-0.741 ± 0.5035-0.649 ± 0.6205-0.681 ± 0.5773
Week 284-0.777 ± 0.5052-0.652 ± 0.6329-0.699 ± 0.5837
Week 308-0.865 ± 0.4811-0.794 ± 0.6311-0.823 ± 0.5655
Week 312-0.888 ± 0.5050-1.000 ± 0.6077-0.949 ± 0.5532
SecondaryChange From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Active Arthritis

The JIA ACR response criteria included six core components, one of which was the number of joints with active arthritis. This was determined using the ACR definition, which identifies active arthritis as any joint with swelling or, in the absence of swelling, limitation of motion accompanied by either pain on motion or tenderness not due to deformity. The active joint count ranged from 0 to 73. The change from baseline of the core study in the number of active joints was measured, with a negative change indicating improvement.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Joints
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Active Arthritis
JointsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-8.4 ± 11.03-6.9 ± 5.26-7.4 ± 7.72
Week 116-8.4 ± 11.48-6.6 ± 4.50-7.3 ± 7.79
Week 128-8.7 ± 11.81-7.3 ± 5.35-7.8 ± 8.24
Week 140-8.4 ± 11.81-7.0 ± 5.44-7.5 ± 8.17
Week 156-8.1 ± 9.77-7.1 ± 5.61-7.5 ± 7.32
Week 180-8.3 ± 11.66-7.0 ± 5.69-7.5 ± 8.29
Week 208-7.0 ± 6.12-6.7 ± 5.38-6.8 ± 5.60
Week 232-7.4 ± 8.48-7.0 ± 5.68-7.1 ± 6.80
Week 260-7.9 ± 10.14-7.5 ± 5.57-7.7 ± 7.36
Week 284-8.4 ± 11.61-7.0 ± 5.57-7.5 ± 8.25
Week 308-8.0 ± 9.70-6.5 ± 4.52-7.1 ± 7.01
Week 312-8.9 ± 11.59-7.5 ± 5.14-8.1 ± 8.48
SecondaryChange From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Limited Range of Motion

The JIA ACR response criteria included six core components, one of which was the number of joints with limited range of motion. A total of 69 joints were assessed for limitation of motion. The change from baseline of the core study in the number of joints with limited range of motion was measured, with a negative change indicating improvement.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Joints
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - Number of Joints With Limited Range of Motion
JointsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-5.5 ± 6.20-5.3 ± 4.23-5.4 ± 4.96
Week 116-5.4 ± 6.24-5.7 ± 4.19-5.6 ± 4.99
Week 128-5.5 ± 6.41-6.0 ± 4.60-5.8 ± 5.28
Week 140-5.7 ± 6.31-6.0 ± 4.99-5.9 ± 5.43
Week 156-5.2 ± 5.68-4.3 ± 8.19-4.6 ± 7.32
Week 180-5.3 ± 6.37-5.5 ± 4.83-5.4 ± 5.38
Week 208-5.1 ± 5.61-5.3 ± 3.92-5.2 ± 4.56
Week 232-4.5 ± 5.42-5.6 ± 3.93-5.2 ± 4.53
Week 260-5.2 ± 6.47-5.9 ± 3.93-5.7 ± 4.90
Week 284-5.1 ± 5.72-6.0 ± 3.88-5.7 ± 4.61
Week 308-5.2 ± 5.46-5.8 ± 3.05-5.5 ± 4.14
Week 312-5.3 ± 6.77-6.3 ± 3.62-5.8 ± 5.17
SecondaryChange From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - CRP Levels

The JIA ACR response criteria included six core components, one of which was CRP levels, an inflammation biomarker. Serum concentrations of CRP were determined, and the change from baseline of the core study was assessed, with negative changes indicating improvement.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · milligram (mg) / liter (L)
Change From Baseline of Core Study CAIN457F2304 in JIA ACR Core Component - CRP Levels
milligram (mg) / liter (L)Group 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-15.238 ± 38.0680-19.788 ± 36.2920-18.187 ± 36.6322
Week 116-11.201 ± 40.1619-21.795 ± 37.5991-17.848 ± 38.5218
Week 128-15.027 ± 40.3989-21.446 ± 38.2870-19.088 ± 38.7812
Week 140-15.867 ± 36.7306-21.211 ± 37.0123-19.325 ± 36.6347
Week 156-13.622 ± 34.4677-21.325 ± 37.3081-18.510 ± 36.1480
Week 180-16.131 ± 38.0479-20.788 ± 36.9842-19.086 ± 37.0716
Week 208-16.907 ± 40.1651-20.694 ± 38.1014-19.303 ± 38.4978
Week 232-15.015 ± 41.4765-20.365 ± 38.9746-18.298 ± 39.5668
Week 260-18.746 ± 48.0621-20.715 ± 42.7106-20.026 ± 44.0482
Week 284-19.974 ± 47.7822-15.530 ± 59.2045-17.212 ± 54.5096
Week 308-21.052 ± 53.0822-21.458 ± 47.6825-21.290 ± 49.0532
Week 312-25.915 ± 55.0448-27.892 ± 53.5661-26.993 ± 52.9390
SecondaryChange From Baseline of Core Study CAIN457F2304 of 27-joint Juvenile Arthritis Disease Activity Score (JADAS-27)

The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 27; where 0= no disease activity and 27= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 57 where 0= no disease activity and 57= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Score on a Scale
Change From Baseline of Core Study CAIN457F2304 of 27-joint Juvenile Arthritis Disease Activity Score (JADAS-27)
Score on a ScaleGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-14.436 ± 7.2274-13.731 ± 7.4131-13.979 ± 7.2876
Week 116-13.984 ± 7.9693-13.632 ± 7.0546-13.763 ± 7.3314
Week 128-14.478 ± 7.7217-14.277 ± 7.3964-14.348 ± 7.4314
Week 140-14.050 ± 7.6609-14.104 ± 7.3246-14.085 ± 7.3683
Week 156-14.027 ± 6.1256-14.158 ± 7.4052-14.111 ± 6.9032
Week 180-14.235 ± 7.6622-13.737 ± 7.5190-13.919 ± 7.5002
Week 208-13.501 ± 5.7531-13.869 ± 7.3790-13.734 ± 6.7665
Week 232-13.064 ± 6.3732-14.669 ± 7.6410-14.049 ± 7.1443
Week 260-13.454 ± 8.9326-15.096 ± 7.9790-14.521 ± 8.2484
Week 284-15.358 ± 7.3767-14.445 ± 8.4302-14.791 ± 7.9550
Week 308-14.437 ± 6.4218-14.647 ± 8.3114-14.560 ± 7.4623
Week 312-15.310 ± 8.3332-17.122 ± 8.2219-16.298 ± 8.1255
SecondaryChange From Baseline of Core Study CAIN457F2304 of 71-joint Juvenile Arthritis Disease Activity Score (JADAS-71)

The JADAS-27 was used for assessment of disease activity, and it included 4 measures: * Physician global assessment of disease activity (VAS range: 0 to 10; where 0=very good and 100=very poor) * Parent/participant global assessment of well-being (VAS range: 0 to 10; 0=very well and 100=very poor) * Count of joints with active disease (range: 0 to 71; where 0= no disease activity and 71= maximum disease activity) * Index of inflammation determined by CRP concentration, calculated as: (CRP (mg/l) -10)/10. Before calculation, CRP values \<10 mg/l were converted to 10 and CRP values \>110 mg/l were converted to 110. The normalized scale ranged from 0 to 10; where 0= no disease activity and 10= maximum disease activity. JADAS-27 score was calculated as the sum of the score of its 4 components, ranging from 0 to 101 where 0= no disease activity and 101= maximum disease activity. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement.

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Score on a Scale
Change From Baseline of Core Study CAIN457F2304 of 71-joint Juvenile Arthritis Disease Activity Score (JADAS-71)
Score on a ScaleGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-17.962 ± 13.2770-16.503 ± 9.0939-17.016 ± 10.6497
Week 116-17.510 ± 14.0289-16.226 ± 8.2331-16.704 ± 10.6429
Week 128-18.595 ± 14.2989-17.083 ± 9.1148-17.619 ± 11.0980
Week 140-17.384 ± 13.8172-16.861 ± 9.0858-17.046 ± 10.8540
Week 156-17.448 ± 11.6294-16.855 ± 9.1102-17.072 ± 9.9946
Week 180-17.709 ± 13.9552-16.556 ± 9.4998-16.977 ± 11.2105
Week 208-16.723 ± 8.8183-16.675 ± 9.0536-16.693 ± 8.8753
Week 232-16.005 ± 10.7335-17.262 ± 9.3685-16.776 ± 9.8143
Week 260-17.239 ± 13.8602-18.019 ± 9.7594-17.746 ± 11.1907
Week 284-19.144 ± 13.7107-17.141 ± 10.3338-17.899 ± 11.5806
Week 308-18.520 ± 12.0126-17.000 ± 9.1449-17.629 ± 10.2499
Week 312-19.810 ± 14.3124-19.622 ± 9.0748-19.707 ± 11.4427
SecondaryChange From Baseline of Core Study CAIN457F2304 in Total Enthesitis Count

The following 16 entheseal sites were assessed for the presence or absence of tenderness (enthesitis) on each side of the body: * Anterior Entheses: Greater trochanter of the Femur; Medial condyle of the femur; Lateral condyle of the femur * Posterior Entheses: Greater tuberosity of humerus; medial epicondyle of humerus; lateral epicondyle of humerus, Achilles tendon; and calcaneal insertion of the plantar fascia. Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites, The total enthesitis count ranged from 0 to 16. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Enthesitis count
Change From Baseline of Core Study CAIN457F2304 in Total Enthesitis Count
Enthesitis countGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-2.5 ± 2.57-2.3 ± 2.30-2.4 ± 2.37
Week 116-2.4 ± 2.36-2.3 ± 2.50-2.4 ± 2.42
Week 128-2.4 ± 2.43-2.3 ± 1.97-2.3 ± 2.13
Week 140-2.5 ± 2.36-2.7 ± 2.43-2.6 ± 2.38
Week 156-2.7 ± 3.03-2.5 ± 2.36-2.2 ± 2.62
Week 180-2.6 ± 2.59-2.5 ± 2.54-2.5 ± 2.53
Week 208-2.4 ± 2.81-2.3 ± 2.562.53 ± 2.63
Week 232-2.5 ± 2.85-2.0 ± 2.28-2.2 ± 2.49
Week 260-2.5 ± 3.54-2.0 ± 1.36-2.2 ± 2.37
Week 284-2.9 ± 3.05-2.0 ± 1.52-2.4 ± 2.21
Week 308-3.2 ± 3.07-2.1 ± 1.25-2.5 ± 2.21
Week 312-2.5 ± 2.32-2.1 ± 1.44-2.3 ± 1.86
SecondaryChange From Baseline of Core Study CAIN457F2304 in Total Dactylitis Count

The dactylitis count was the number of fingers and toes presenting with swelling and inflammation. Swelling and inflammation on examination was recorded as either present (1) or absent (0) for each of the 20 sites, The total dactylitis count ranged from 0 to 20. The change from baseline of the core study was assessed. A negative change from baseline indicated improvement

Time frame:
Baseline of the core study, Week 104 (start of extension study), 116, 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · Dactylitis count
Change From Baseline of Core Study CAIN457F2304 in Total Dactylitis Count
Dactylitis countGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 104-1.3 ± 1.94-0.4 ± 1.97-0.7 ± 1.99
Week 116-1.5 ± 2.04-0.5 ± 2.05-0.9 ± 2.08
Week 128-1.8 ± 2.39-0.5 ± 2.23-0.9 ± 2.35
Week 140-1.6 ± 2.42-0.6 ± 2.09-1.0 ± 2.24
Week 156-1.6 ± 2.23-0.7 ± 2.07-1.0 ± 2.15
Week 180-1.8 ± 2.410.0 ± 4.15-0.6 ± 3.71
Week 208-1.6 ± 2.42-0.3 ± 0.87-0.8 ± 1.70
Week 232-1.5 ± 2.42-0.4 ± 0.88-0.8 ± 1.70
Week 260-1.2 ± 2.04-0.3 ± 0.84-0.6 ± 1.43
Week 284-1.2 ± 2.13-0.3 ± 0.95-0.6 ± 1.52
Week 308-0.9 ± 1.700.1 ± 0.56-0.3 ± 1.22
Week 312-1.1 ± 1.83-0.2 ± 0.39-0.6 ± 1.29
SecondarySerum Concentrations of Secukinumab Over Time

Serum concentration of secukinumab over time. Blood samples for pharmacokinetics were taken pre-dose at the scheduled time points.

Time frame:
Pre-dose at Week 128, 140, 156, 180, 208, 232, 260, 284 , 308 and 312. Study week is defined with respect to the core study.
Reported as:
Mean · microgram (ug)/milliliter (mL)
Serum Concentrations of Secukinumab Over Time
microgram (ug)/milliliter (mL)Group 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Week 12821.4 ± 8.5726.4 ± 9.7824.8 ± 9.58
Week 15620.8 ± 8.7626.6 ± 11.624.3 ± 10.8
Week 18021.0 ± 10.425.2 ± 9.2823.7 ± 9.75
Week 20820.5 ± 6.8226.7 ± 11.424.3 ± 10.2
Week 23219.7 ± 7.0624.2 ± 11.622.5 ± 10.2
Week 26016.0 ± 6.9425.4 ± 8.9921.5 ± 9.32
Week 28413.5 ± 7.9927.5 ± 7.4821.7 ± 10.3
Week 30812.5 ± 5.3127.5 ± 14.718.8 ± 12.4
Week 31214.6 ± 4.7925.4 ± 18.519.5 ± 13.4
SecondaryNumber of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs) of Secukinumab

Number of participants with treatment-emergent Anti-Drug Antibodies (ADAs) of secukinumab. Blood samples were collected for immunogenicity (anti-AIN457 antibodies) assessments.

Time frame:
From baseline of the core study up to Week 312. Study week is defined with respect to the core study.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs) of Secukinumab
ParticipantsGroup 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal Secukinumab Dose
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADAs) of Secukinumab066

Adverse events

Collected over From first dose of secukinumab in the extension study up to 84 days after last dose of secukinumab, assessed up to approximately 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Any Secukinumab 75 mg0/19 (0%)0/19 (0%)15/19 (78.9%)
Any Secukinumab 150 mg0/43 (0%)4/43 (9.3%)28/43 (65.1%)
Any Secukinumab 300 mg0/16 (0%)0/16 (0%)11/16 (68.8%)
Any Secukinumab0/54 (0%)4/54 (7.4%)43/54 (79.6%)
Most frequent serious events
Most frequent serious events
EventAny Secukinumab 75 mgAny Secukinumab 150 mgAny Secukinumab 300 mgAny Secukinumab
Crohn's diseaseGastrointestinal disorders0/191/430/161/54
Acute sinusitisInfections and infestations0/191/430/161/54
ConcussionInjury, poisoning and procedural complications0/191/430/161/54
Head injuryInjury, poisoning and procedural complications0/191/430/161/54
Subdural haematomaInjury, poisoning and procedural complications0/191/430/161/54
Cerebral haemorrhageNervous system disorders0/191/430/161/54
Subarachnoid haemorrhageNervous system disorders0/191/430/161/54
NephrolithiasisRenal and urinary disorders0/191/430/161/54
Urethral haemorrhageRenal and urinary disorders0/191/430/161/54
Most frequent other events
Showing 10 of 87
Most frequent other events
EventAny Secukinumab 75 mgAny Secukinumab 150 mgAny Secukinumab 300 mgAny Secukinumab
NasopharyngitisInfections and infestations2/198/434/1613/54
COVID-19Infections and infestations1/199/433/1613/54
ArthralgiaMusculoskeletal and connective tissue disorders4/197/433/1611/54
Pain in extremityMusculoskeletal and connective tissue disorders1/198/430/168/54
Abdominal pain upperGastrointestinal disorders3/194/430/166/54
DiarrhoeaGastrointestinal disorders1/195/431/167/54
Upper respiratory tract infectionInfections and infestations2/195/430/167/54
AstigmatismEye disorders0/190/432/162/54
Alanine aminotransferase increasedInvestigations0/191/432/163/54
Eosinophil count increasedInvestigations0/190/432/162/54

Baseline characteristics

Participants who enrolled in the extension study. One patient enrolled with planned treatment secukinumab150 mg discontinued the study before receiving study treatment. This patient was not included in the analysis.

Age, Continuous
Age, Continuous(Years)Group 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal
Mean9.5 ± 3.4914.1 ± 2.0212.5 ± 3.40
Sex: Female, Male
Sex: Female, Male(Participants)Group 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal
Female81018
Male112536
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Group 1- Secukinumab 75 mgGroup 2 - Secukinumab 150 mgTotal
White193352
Other022
08

Study locations

23 sites
  • St Lukes Intermountain Research Center
    Boise, Idaho 83702, United States
  • Cincinnati Childrens Hospital
    Cincinnati, Ohio 45229, United States
  • Legacy Emanuel Research Hospital Portland
    Portland, Oregon 97232, United States
  • Novartis Investigative Site
    Brussels, 1200, Belgium
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Freiburg im Breisgau, 79106, Germany
  • Novartis Investigative Site
    Hamburg, 22081, Germany
  • Novartis Investigative Site
    Saint Augustin, 53757, Germany
  • Novartis Investigative Site
    Genova, GE 16147, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Krakow, 31503, Poland
  • Novartis Investigative Site
    Moscow, 119991, Russia
  • Novartis Investigative Site
    Saint Petersburg, 194100, Russia
  • Novartis Investigative Site
    Voronezh, 394036, Russia
  • Novartis Investigative Site
    Yekaterinburg, 620149, Russia
  • Novartis Investigative Site
    Panorama, Western Cape 7500, South Africa
  • Novartis Investigative Site
    Cape Town, 7925, South Africa
  • Novartis Investigative Site
    Santiago de Compostela, Galicia 15706, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Istanbul, Halkali 34303, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, TUR 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, 06230, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, 34093, Turkey (Türkiye)
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Nov 2024, 65 months.

Results were first posted in May 2025, 6 months after primary completion.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 65 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2018
First posted
Dec 7, 2018
StartActual
Jun 7, 2019
Primary completionActual
Nov 7, 2024
CompletionActual
Nov 7, 2024
Results first posted
May 23, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03769168
Responsible party
Sponsor
First posted
Dec 7, 2018
Start date
Jun 7, 2019
Primary completion
Nov 7, 2024
Completion
Nov 7, 2024
Results posted
May 23, 2025
Last update
Oct 16, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion